Raadpleeg ook literatuurlijst niet-toxische middelen en behandelingen specifiek bij baarmoederkanker en baarmoederhalskanker van arts-bioloog drs. Engelbert Valstar
27 mei 2020: Ascopost
Klik op de vergemaakte abstractnummers voor de abstracten:
Session: Gynecologic Cancer—Cervical Cancer
6006 Long-term oncological safety of sentinel lymph node biopsy in early-stage cervical cancer. V Balaya, B Guani, L Magaud, et al
- Patients with early-stage cervical cancer were randomized to undergo bilateral sentinel lymph node (SLN) biopsy alone or bilateral pelvic lymphadenectomy (BPL). No patients had positive SLN or non-SLN biopsies. Patients in the BPL group were more likely than those in the SLN group to have tumors >20 mm and to require postoperative radiochemotherapy. The 5-year disease-free survival and disease-specific survival (DSS) were not significantly different between the two groups. The only independent predictor of DSS was final FIGO stage.
- Patients with early-stage cervical cancer and negative bilateral SLN biopsy can safely avoid full lymphadenectomy.
6007 Sequential chemoradiation versus radiation alone or concurrent chemoradiation in adjuvant treatment after radical hysterectomy for stage IB1-IIA2 cervical cancer (STARS Study): A randomized, controlled, open-label, phase III trial. H Huang, Y Feng, T Wan, et al
- Patients with FIGO 2009 stage IB1–IIA2 cervical cancer with at least one adverse factor after radical hysterectomy were randomized to receive adjuvant radiation alone, concurrent chemoradiation, or sequential chemoradiation. The rate of disease-free survival at 3 years was 90.0% in the sequential chemoradiation group, 85.0% in the concurrent chemoradiation group, and 82.0% in the radiation-only group. In addition, sequential chemoradiation was associated with longer overall survival compared with radiation alone.
- Sequential chemoradiation was associated with a higher disease-free survival rate and lower risk of cancer death compared with radiation alone in women with early-stage cervical cancer following surgical treatment.
6036 Gut microbiome diversity as an independent predictor of survival in cervical cancer patients receiving chemoradiation. TT Sims, MB Alam, T Karpinets, et al
- Patients with cervival cancer receiving standard chemoradiation underwent evaluation of the fecal microbiome to identify independent gut microbial risk factors. BMI and fecal sample diversity were shown to be independent prognostic factors for recurrence-free and overall survival.
- The diversity of the gut microbiome predicts overall survival in patients with cervival cancer receiving standard chemoradiation after accounting for BMI. Further studies are needed to evaluate the effect of gut microbiome diversity on treatment outcomes.
TPS6095 Phase Ib/II trial of tisotumab vedotin (TV) ± bevacizumab (BEV), pembrolizumab (PEM), or carboplatin (CBP) in recurrent or metastatic cervical cancer (innovaTV 205/ENGOT-cx8/GOG-3024). I Vergote, N Concin, MR Mirza, et al
- Patients with recurrent/metastatic cervical cancer are being enrolled in this phase Ib/II trial to investigate the use of tisotumab vedotin (TV), an investigational antibody–drug conjugate. Preliminary data for TV monotherapy indicated a positive benefit-to-risk profile, and TV is now being investigated in combination with other conventional therapies.
- The phase I dose-escalation part of the study will be used to identify to the optimal dose for phase II, where TV will be administered with bevacizumab, pembrolizumab, or carboplatin. The primary endpoint of the study will be the objective response rate.
TPS6096 ENGOT-cx11/KEYNOTE-A18: A phase III, randomized, double-blind study of pembrolizumab with chemoradiotherapy in patients with high-risk locally advanced cervical cancer. D Lorusso, N Colombo, RL Coleman, et al
- Enrollment is currently ongoing for this randomized phase III trial of pembrolizumab versus placebo with concurrent chemoradiotherapy among patients with high-risk locally advanced cervical cancer. Treatment will be continued for 20 cycles or until progression or toxicity.
- The two primary endpoints of the study are progression-free and overall survival.
e18025 Hormonal rehabilitation in patients with endothelial and cervical cancers. NV Chernikova, TI Moiseenko, AI Shikhlyarova, et al
Session: Clinical Science Symposium—Uterine Cancer
6010 A randomized phase II study of cabozantinib and nivolumab versus nivolumab in recurrent endometrial cancer. S Lheureux, D Matei, PA Konstantinopoulos, et al
- Patients with recurrent endometrial cancer treated with at least one prior platinum-based chemotherapy were randomized to receive cabozantinib plus nivolumab (arm A) or nivolumab alone (arm B). An exploratory cohort of patients with carcinosarcoma or prior immunotherapy received combination treatment (arm C). The median progression-free survival was 5.3 months in arm A versus 1.9 months in arm B. The clinical benefit was signiifcantly greater in arm A than arm B. Among the arm C patients with carcinosarcoma (n = 9), there was 1 partial response and 4 patients had stable disease. Among arm C patients who had received prior immunotherapy (n = 20), there were 6 responses and 8 patients with stable disease. Most adverse events in arm A were grade 1 or 2.
- The use of cabozantinib plus nivolumab improves progression-free survival compared with nivolumab alone in women with heavily pretreated recurrent endometrial cancer. Further study is ongoing to identify predictive immune biomarkers of response in the tumor samples.
Session: Gynecologic Cancer—Other Cancer
6090 Evaluation of treatment patterns and prognosis in correlation with age in patients with vulvar cancer: A subset analysis of the AGO-CaRE-1 study. K Prieske, LL Woelber, MZ Muallem, et al
- The authors evaluated the impact of age on prognosis and treatment patterns among women with primary squamous cell vulvar cancer (VSCC). Women aged ≥70 years were more likely than younger patients to present with more advanced-stage tumors, larger tumor diameter, poorer ECOG status, higher tumor grade, and a higher rate of nodal involvement. These older women were also more likely than younger women to have HPV-negative tumors. Disease recurrence, especially isolated vulvar recurrence, was significanlty more common in women aged ≥70 years compared with younger women. Age was shown to be an independent prognostic factor for disease-free survival (DFS), with 2-year DFS decreasing as age increased. The hazard ratio for the risk for death or recurrence was 3.21 in women aged ≥70 years compared with women aged <50 years (P < .001).
- Among women with VSCC, older women present with more advanced tumors and have poorer outcomes than younger patients. The delayed time to diagnosis may be due to self-awareness but also due to differences in tumor biology.
- ASCO 2021: aanbevolen abstracten bij eierstokkanker en baarmoederhalskanker, vulvakanker, endometriumkanker en baarmoederkanker copy 1
- ASCO 2020: aanbevolen abstracten bij eierstokkanker en baarmoederhalskanker, vulvakanker en endometriumkanker (baarmoederkanker) copy 1
- ASCO 2021: aanbevolen abstracten bij eierstokkanker en baarmoederhalskanker, vulvakanker, endometriumkanker en baarmoederkanker
- ASCO 2020: aanbevolen abstracten bij eierstokkanker en baarmoederhalskanker, vulvakanker en endometriumkanker (baarmoederkanker)
- Belangrijke abstracten van ASCO 2018 gerelateerd aan eierstokkanker, baarmoederkanker en baarmoederhalskanker. copy 1
- Belangrijke abstracten van ASCO 2018 gerelateerd aan eierstokkanker, baarmoederkanker en baarmoederhalskanker.
- ASCO 2023: aanbevolen abstracten voor gynaecologische vormen van kanker, waaronder baarmoederkanker, baarmoederhalskanker, eierstokkanker door vooraanstaande medisch specialisten